Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) News
Filter TEVA News Items
TEVA News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest TEVA News From Around the Web
Below are the latest news stories about Teva Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TEVA as an investment opportunity.
A month ago, about 70% of the COVID-19 patients being treated at the 13 hospitals that make up the Hackensack Meridian Health system in New Jersey received hydroxychloroquine as part of their care.
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report, demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content. The report details Teva’s 2019 efforts to lesse
Three Buffett stocks, in particular, are trouncing Berkshire in 2020. While the COVID-19 pandemic has hurt many companies, Amazon's business has thrived. The impact of the global novel coronavirus outbreak has turned Amazon's business upside down -- mostly in a good way.
Frequently, buying stocks trading below their fundamental net worth can yield lucrative rewards for investors.
Teva Pharmaceutical Industries (NYSE: TEVA) is a well known generic drugmaker that's attracted the attention of a number of well-known investors in the past. Most notably, Warren Buffett's Berkshire Hathaway bought shares of the company a number of years ago due, in no small part due to how cheap the stock was at the time. Teva's business can be split up into two main areas: its generics business and its own branded drug products.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he wouldn't buy Teva Pharmaceutical Industries Ltd (NYSE: TEVA). He explained that it's a generic drugmaker and those stocks are pretty awful in comparison to Merck & Co., Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE) and Bristol-Myers Squibb Co (NYSE: BMY).Instead of Oxford Industries Inc (NYSE: OXM), Cramer would rather buy PVH Corp (NYSE: PVH).Cramer likes Amgen, Inc. (NASDAQ: AMGN) and its new oncological franchise.He prefers Advanced Micro Devices, Inc. (NASDAQ: AMD) over Intel Corporation (NASDAQ: INTC). He believes AMD will take some market share from Intel with its new chips.Cramer said the CEO of General Electric Company (NYSE: GE) is doing a fantastic job against tremendous circumstances, but he doesn't see the investment in t...
No matter how dire things may have appeared in previous bear markets, bull-market rallies eventually erase all evidence of downward moves in the stock market. Also keep in mind that you don't have to be rich to generate a handsome return from the stock market. With the exception of the oil and gas industry, there's probably not a harder-hit industry lately than bank stocks.
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) (“Teva”), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.m., New York time), as previously announ
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic.